
Lexicon Pharmaceuticals (LXRX) Stock Forecast & Price Target
Lexicon Pharmaceuticals (LXRX) Analyst Ratings
Bulls say
Lexicon Pharmaceuticals has shown positive momentum with favorable topline results from its Phase 2b PROGRESS clinical trial for pilavapadin, indicating effective outcomes for patients suffering from diabetic peripheral neuropathic pain (DPNP). The interest from potential partners, driven by the drug's significant market potential—highlighted by approximately 9 million diagnosed cases in the U.S.—suggests a robust commercial opportunity ahead. Additionally, the successful identification of an optimal dose for pilavapadin positions the company favorably for future development phases and enhances the outlook for its earlier-stage drug candidate, LX9851, focused on obesity and cardiometabolic conditions.
Bears say
Lexicon Pharmaceuticals has faced significant challenges in clinical trials, as the results from its RELIEF DPN-1 study showed disappointing data for the 20 mg dose, which failed to demonstrate statistical significance compared to placebo, leading to investor skepticism. The company's future is further threatened by potential failures or inconclusive results from ongoing clinical trials, which could hinder the path to market approval for its drug candidates. Additionally, the risk of inadequate funding and the possibility of dilutive capital raises may negatively impact the company's financial stability and ability to advance its development pipeline.
This aggregate rating is based on analysts' research of Lexicon Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Lexicon Pharmaceuticals (LXRX) Analyst Forecast & Price Prediction
Start investing in Lexicon Pharmaceuticals (LXRX)
Order type
Buy in
Order amount
Est. shares
0 shares